Transtinib is an irreversible EGFR tyrosine kinase inhibitor effective against NSCLC with L858R/T790M mutations. It demonstrates potent activity in both cellular assays and animal xenograft models, making it a valuable tool for studying resistant EGFR-driven cancers in preclinical research.